Roivant Sciences Ltd

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Roivant Sciences reports strong Q1 earnings and explores new opportunities

Roivant Sciences demonstrated strong financial performance, with positive results for key programs and a substantial cash position. While facing challenges in patent litigation and DTC campaign optimization, the company has opportunities to leverage payer work, explore new therapeutic potentials, and capitalize on transaction opportunities.

ROIV reports positive trial results and potential in autoimmune diseases

ROIV's earnings call highlights positive trial results, potential in autoimmune diseases, and upcoming Phase III study results. The company acknowledges challenges in proving efficacy in lupus but is optimistic about brepocitinib's potential in various indications.

Roivant Sciences doubles revenue in Q3, VTAMA gains traction

Roivant Sciences delivered strong financial results and progress in its pipeline, particularly with the successful launch of VTAMA and enrollment in key studies.
While facing challenges in market penetration and patient behavior trends, the company's strategic focus on innovation and financial discipline positions it for future success.
By leveraging opportunities in expanding indications, advancing pipeline assets, and strategic collaborations, Roivant is poised for sustained growth and value creation.

Roivant Sciences reports robust Q4 earnings and strategic growth outlook

Roivant Sciences delivered a strong financial performance with notable achievements in clinical programs and a robust cash position, indicating stability and growth potential.
While facing challenges in patient consent for biomarker analysis and legal uncertainties, the company is strategically positioned to leverage opportunities in expanding its pipeline and exploring new markets.
With a focus on balancing operational challenges and pursuing strategic growth initiatives, Roivant Sciences remains well-positioned for future success in the biopharmaceutical industry.

Roivant Sciences excels in Q1 2024 with promising autoimmune therapies

Roivant Sciences demonstrated strong performance and promising results in Q1 2024 across multiple programs
Brepocitinib's unique mechanism positions it as a potential leader in autoimmune therapies, with significant market opportunities
Capital decisions post-Immunovant data and pricing strategy alignment present challenges for Roivant
Opportunities lie in rapid commercial launches, blockbuster potential in orphan indications, and prescription acceleration strategies

Roivant Sciences excels in Q2 with $7B cash post-sale

Roivant Sciences delivered a solid performance in Q2 2024, showcasing financial strength, positive clinical outcomes, and strategic focus on value creation. While facing challenges in margin optimization and market competition, the company is well-positioned to leverage opportunities in unmet medical needs and strategic partnerships for growth.

Roivant Sciences reports strong Q3 performance and outlines growth plans

Roivant Sciences showcased strong performance with key successes and efficient development models. The company faces challenges in certain clinical trials but remains optimistic about growth opportunities. By focusing on strategic growth and efficient execution, Roivant aims to capitalize on its promising pipeline and commercial potential.

Roivant Sciences excels in Q4, eyes blockbuster sales and strategic partnerships

Roivant Sciences is strategically positioned with a focus on maximizing pipeline opportunities, prioritizing data-driven decisions, and capitalizing on the differentiation potential of brepocitinib.

Roivant Sciences excels in Q2 with strong pipeline and financials

Roivant Sciences showcased strong financial performance, a robust late-stage pipeline, and positive clinical trial data in Q2 2025.
The company faces challenges in managing expectations, pricing strategies, and balancing capital return with R&D investments.
Opportunities for growth include upcoming data releases, strategic partnerships, and optimizing business strategies for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimmer - Chief Executive Officer, Priovant Conference Call Participants Louise Chen - Cantor Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Andy Chen - Wolfe Research Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21.

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant's batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor.

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Organon & Co

Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.

Roivant Flips a Skin Drug to Organon

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?

BASEL, Switzerland and LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. Pulmovant presented data from the proof-of-concept Phase 1b ATMOS study during the ERS Congress in Vienna, Austria.

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pulmovant, a Roivant (Nasdaq: ROIV) company, today announced the presentation of data from the proof-of-concept Phase 1b ATMOS1 study during the ERS Congress in Vienna, Austria. ATMOS (NCT03754660) evaluated mosliciguat, a potential first-in-class, inhaled sGC activator with targeted delivery to the lungs and once-daily administration, in PH patients.

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.

Roivant Provides Update on Graves' Disease Development Program

Carnival

SM Energy

The 200-day Simple Moving Average is an important technical indicator that can signal potential bullish sentiment and breakout opportunities for stocks. The 200-day SMA can also act as support or resistance levels for stocks, and can help signal potential entry and exit points for traders. SA Quant has identified 3 stocks trading near their 200-day SMAs, backed by solid fundamentals, including value, and Quant strong buy recommendations.

Top Stocks Near Their 200-Day SMA

Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to develop and commercialize medicines", with a focus on unearthing strong drug candidates for lucrative exits. Key drugs in Roivant's pipeline include VTAMA, Batoclimab, and Breproctinib, each facing competition and uncertainties in their respective markets.

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference Call Participants Allison Bratzel - Piper Sandler Brian Cheng - JPMorgan Dave Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Louise Chen - Cantor Yatin Suneja - Guggenheim Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21.

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates

Alnylam Pharmaceuticals

Clover Health Investments

CRISPR Therapeutics

Enovix Corporation

General American Investors

Halliburton

Logistic Properties Of The Americas

Adams Natural Resources Fund Inc

POET Technologies Inc

Uranium Royalty Corp

Voyager Therapeutics

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.

The 'Undercovered' Dozen From June 1-6

Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation value of $5-10 billion against Moderna and Pfizer.

Roivant Sciences: Executing On Huge Buyback Program With More To Come

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2023 Earnings Conference Call May 30, 2024 8:00 AM ET Company Participants Abby Beier - Principal, Strategic Finance Matt Gline - Chief Executive Officer Frank Torti - Managing Director, Vant Chair Mayukh Sukhatme - President and Chief Investment Officer Conference Call Participants David Risinger - Leerink Partners Louise Chen - Cantor Fitzgerald Allison Bratzel - Piper Sandler Corinne Johnson - Goldman Sachs Brian Cheng - JPMorgan Yaron Werber - TD Cowen Yatin Suneja - Guggenheim Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25.

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update.

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

AbbVie

Cytokinetics

Eli Lilly

Novo Nordisk

Pfizer

Viking Therapeutics

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare

DaVita

Finding firms with strong growth potential is essential for healthcare investors looking for large profits. Three exceptional firms have surfaced as strong healthcare stocks.

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026

BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung). Approximately 200,000 people in the U.S. (and more than 1 million worldwide) are estimated to have sarcoidosis, an i.

News for Roivant Sciences Ltd Stock (ROIV)